Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- May 15 2003
- Volume 10
- Issue 9
PHARMACEUTICAL STOCKWATCH
Advertisement
Articles in this issue
about 18 years ago
Postwar Economy Refocuses Attentionabout 18 years ago
Model Portfolio Series: Conservative Growthabout 18 years ago
How Does Your Financial IQ Measure Up?about 18 years ago
History Provides Lessons in Investingabout 18 years ago
Read the Market's Long-Term Performanceabout 18 years ago
Less Is More When Buying Stock Spinoffsabout 18 years ago
Weigh the Aspects of Variable Annuitiesabout 18 years ago
Maximize Your Sale of Stocks at a Lossabout 18 years ago
Realize the Importance of Market Timingabout 18 years ago
Speed Through Annual Reports Like a ProAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5